NHS Rotherham Clinical Commissioning Group
Framework of NICE Guidance
October 2014

QS73	Fertility problems	Quality standards	Fertility
PH55	Oral health: approaches for local authorities and their partners to improve the oral health of their communities	Public health guidance	Oral health
TA321	Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma	Technology appraisal guidance	Skin cancer
QS71	Transient loss of consciousness	Quality standards	Transient loss of consciousness
CG186	Multiple sclerosis	Clinical guidelines	Multiple sclerosis

CG187	Acute heart failure	Clinical guidelines	Heart failure
QS74	Head injury	Quality standards	Head injuries
CG188	Gallstone disease	Clinical guidelines	Cholelithiasis and cholecystitis

Guideline No	Title	Summary	Implications & Action	Completed Actions
TA321	Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma	**Dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma only if the company provides dabrafenib with the discount agreed in the patient access scheme**	Implications for Secondary care and\or specialist commissioning no direct implications for the CCG	Completed